Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

Three important sequences (FLAIR, T2, T1 with contrast agent) in the assessment of glioblastoma

University Hospital Tübingen: Advancing MRI Efficiency in Glioblastoma Care with Deep Learning

This study explores the use of deep learning (DL) to optimize MRI protocols for glioblastoma patients. Glioblastomas, known for being the most…

Picture of Dr. Maurice Heimer, radiology resident

Insights into the BORN Project: Development and Successes with Dr. Maurice Heimer

The BORN-project of the Bavarian Center for Cancer Research (BZKF) is making swift progress in its second funding phase. A key aspect of the project…

A Closer Look at the BZKF BORN-Project: Interview with Dr. Maurice Heimer from the Clinic and Polyclinic for Radiology at the LMU Klinikum

The Bavaria-wide Oncological Radiology Network (BORN) is now in its second funding phase and is making rapid progress. The project was initiated in…